IO Biotech, Inc. (IOBT )

Currency in USD Disclaimer
$2.16 +$0.88 (68.75%)
Closed 08/15/2025
$1.33
$2.21
$0.66
$2.48

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol IOBT
  • Company IO Biotech, Inc.
  • Price $2.16
  • Changes Percentage 68.75
  • Change 0.88
  • Day Low $1.33
  • Day High $2.21
  • Year High $2.48
  • Year Low $0.66
  • Market Cap $119,244,447
  • Price Avg 50 EMA (D) $1.65
  • Price Avg 200 EMA (D) $1.13
  • Exchange NASDAQ
  • Volume 358,051
  • Average Volume 319,732
  • Open $1.4
  • Previous Close $1.28
  • EPS -1.49
  • PE -1.21
  • Earnings Announcement 2025-08-08 12:00:00
  • Shares Outstanding $65,880,910

Company brief: IO BIOTECH, INC. (IOBT )

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

IOBT Corporation News

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 14, 2025 at 8:05 pm ET

globenewswire.com -- Announced clinical improvement in progression free survival observed in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (pembrolizumab) for the treatment of first-line advanced melanoma, but stati...

Income Statement